{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:11:43Z","timestamp":1792239103793,"version":"4.4.0"},"reference-count":28,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T00:00:00Z","timestamp":1616976000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The prognosis of relapsed acute lymphoblastic leukemia (ALL) after allogeneic transplantation is dismal when treated with conventional approaches. While single\u2010target CD19 or CD22 chimeric antigen receptor (CAR) T\u2010cell therapy has achieved high complete remission (CR) rates in refractory\/relapsed B\u2010ALL, it could not maintain a durable remission in most patients. To prolong relapse\u2010free survival, we sequentially combined CD19 and CD22 CAR\u2010T cells to treat post\u2010transplant relapsed B\u2010ALL patients with both CD19\/CD22 antigen expression on lymphoblasts. Patient\u2010derived donor cells were collected to produce CAR\u2010T cells that were transfected by lentiviral vectors encoding second generation CARs composed of CD3\u03b6 and 4\u20131BB. The second T\u2010cell infusion was scheduled at least 1\u2009month, and usually within 6\u00a0months after the first CAR\u2010T treatment. Twenty\u2010seven adult and pediatric patients, including 11 (41%) with extramedullary diseases (EMD), received the first CD19 CAR\u2010T and 23 (85%) achieved CR. Subsequently, 21 out of 27 patients received the second CD22 CAR\u2010T and were followed\u2010up for a median of 19.7 (range, 5.6\u201327.3) months; 14 cases remained in CR, seven relapsed and two of them died from disease progression; Kaplan\u2013Meier survival analysis showed overall survival and event\u2010free survival rates of 88.5% and 67.5%, respectively, at both 12\u2009months and 18\u2009months. CAR\u2010T associated graft\u2010versus\u2010host disease (GVHD) occurred in 23% of patients, with 8% new\u2010onset acute GVHD and 15% persistent or worsened pre\u2010existing cGVHD before CAR\u2010T. This combination strategy of sequential CD19 and CD22 CAR\u2010T therapy significantly improved the long\u2010term survival in B\u2010ALL patients who relapsed after transplantation.<\/jats:p>","DOI":"10.1002\/ajh.26160","type":"journal-article","created":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T17:53:56Z","timestamp":1615917236000},"page":"671-679","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":123,"title":["Combination of\n                    <scp>CD19<\/scp>\n                    and\n                    <scp>CD22 CAR\u2010T<\/scp>\n                    cell therapy in relapsed B\u2010cell acute lymphoblastic leukemia after allogeneic transplantation"],"prefix":"10.1002","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9982-7099","authenticated-orcid":false,"given":"Shuangyou","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Hematology Beijing Boren Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biping","family":"Deng","sequence":"additional","affiliation":[{"name":"Cytology Laboratory Beijing Boren Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhichao","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Hematology Beijing Boren Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuehui","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Hematology Beijing Boren Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"An","sequence":"additional","affiliation":[{"name":"Department of Hematology Beijing Boren Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology Beijing Boren Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Hematology Beijing Boren Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinjian","family":"Yu","sequence":"additional","affiliation":[{"name":"Medical Laboratory Beijing Boren Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingzhen","family":"Chen","sequence":"additional","affiliation":[{"name":"Medical Laboratory Beijing Boren Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Bone Marrow Transplantation Beijing Boren Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex H.","family":"Chang","sequence":"additional","affiliation":[{"name":"Clinical Translational Research Center, Shanghai Pulmonary Hospital Tongji University School of Medicine  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunrong","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Hematology Beijing Boren Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,3,29]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702555"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.16.3675"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.351"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0438-z"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008226"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.145"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4441"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0488-7"},{"key":"e_1_2_8_13_1","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Acute Lymphoblastic Leukemia. Version 5","author":"National Comprehensive Cancer Network","year":"2017"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0571-y"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.09.001"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.12.001"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0280-y"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-703751"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129411"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-113126"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000017"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.5929"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61403-3"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI86721"},{"key":"e_1_2_8_26_1","article-title":"Tolerance and efficacy of autologous or donor\u2010derived T cells expressing CD19 chimeric antigen receptors in adult B\u2010ALL with extramedullary leukemia","volume":"4","author":"Dai H","year":"2015","journal-title":"Onco Targets Ther"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4258"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph8020230"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-506741"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.26160","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.26160","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.26160","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T01:29:49Z","timestamp":1693099789000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.26160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,29]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1002\/ajh.26160"],"URL":"https:\/\/doi.org\/10.1002\/ajh.26160","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,29]]},"assertion":[{"value":"2020-12-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}